IP Library Granted Patent US 9,708,587
Granted Patent B2
US 9,708,587 · App. 14/794,249 · Granted Jul 18, 2017

P450-BM3 variants with improved activity

Inventors: Robert Osborne (Oakland, CA); Vesna Mitchell (San Jose, CA); Khin Yu Naing Htwe (Daly City, CA); Xiyun Zhang (Fremont, CA); Erika M. Milczek (New York, NY); Jeffrey C. Moore (Westfield, NJ)
Assignee: Codexis, Inc.
C12N9/0071C12N9/0042C12Y106/02004C12Y114/14001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,708,587
App. No.
14/794,249
Granted
Jul 18, 2017
Kind
B2
Abstract

The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.

Claims (12)

1. A recombinant cytochrome P450-BM3 variant comprising the amino acid sequence of SEQ. ID NO: 16.

2. The recombinant cytochrome P450-BM3 variant of claim 1 , wherein said variant oxidizes an organic substrate selected from the group consisting of nifedipine, propranolol, verapamil, and diclofenac.

3. An isolated polynucleotide comprising, a nucleotide sequence encoding the recombinant cytochrome P450-BM3 variant of claim 1 .

4. The isolated polynucleotide of claim 3 , wherein said nucleotide sequence comprises the nucleotide sequence of SEQ ID NO: 15.

5. An expression vector comprising the polynucleotide of claim 3 .

6. The vector of claim 5 , wherein said polynucleotide is operably linked with regulatory sequences suitable for expression of said polynucleotide sequence in a suitable host cell.

7. The vector of claim 6 , wherein said host cell is a prokaryotic or eukaryotic cell.

8. The vector of claim 7 , wherein said host cell is a prokaryotic cell.

9. The vector of claim 7 , wherein said host cell is Escherichia coli.

10. An isolated host cell comprising the vector of claim 5 .

11. A method for producing at least one a recombinant cytochrome P450-BM3 variant comprising culturing the host cell of claim 10 under conditions such that the recombinant cytochrome P450-BM3 variant is produced.

12. The method of claim 11 , further comprising the step of recovering said recombinant cytochrome P450 variant.

Assignments (4)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2018
From: MILCZEK, ERIKA M.; MOORE, JEFFREY C.
To: MERCK SHARP & DOHME CORP.
Reel/Frame 044990/0815 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2018
From: MERCK SHARP & DOHME CORP.
To: CODEXIS, INC.
Reel/Frame 044991/0278 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2015
From: OSBORNE, ROBERT; MITCHELL, VESNA; HTWE, KHIN YU NAING; ZHANG, XIYUN
To: CODEXIS, INC.
Reel/Frame 036519/0420 →
Continuity (2)
Provisional Application 62022442 · Jul 9, 2014
Related Publication 20160010065A1 · Jan 14, 2016